Valuation: Exagen Inc.

Market Cap 111M 96.89M 89.44M 83.52M 157M 10.46B 161M 1.08B 416M 5.16B 416M 406M 17.92B P/E 2026 *
-6.56x
P/E 2027 * -8.88x
Enterprise Value 111M 96.89M 89.44M 83.52M 157M 10.46B 161M 1.08B 416M 5.16B 416M 406M 17.92B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 1.39x
Free-Float
57.84%
Yield 2026 *
-
Yield 2027 * -
1 day+3.38%
1 week+7.47%
Current month-4.62%
1 month-4.62%
3 months+79.25%
6 months-20.57%
Current year-21.88%
1 week 4.31
Extreme 4.31
5.01
1 month 4.11
Extreme 4.11
5.55
Current year 2.59
Extreme 2.59
6.75
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
15.41
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 2022-10-16
Director of Finance/CFO 57 2024-08-31
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Chairman 72 2023-01-18
Director/Board Member 63 2019-07-29
Director/Board Member 56 2021-06-16
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

37,500 0.1552%
06-08Free

Director

37,500 0.1552%
06-08Free

Director

37,500 0.1552%
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%+7.47%-31.95%+72.73% 111M
+1.49%+16.61%+57.92%+444.15% 37.51B
+0.88%+7.40%+4.09%+13.63% 22.26B
+2.69%+4.59%-21.46%-41.86% 6.97B
-2.64%+6.28%+4.13%+79.63% 4.78B
-2.50%+0.68%+18.96%+49.32% 2.99B
-2.81%+22.39%-26.52%+963.17% 2.07B
-0.04%+26.74%+94.19%-10.95% 1.85B
+3.34%+7.02%+30.83%-22.60% 1.7B
+2.30%+3.87%+19.43%-2.14% 1.64B
Average +0.63%+8.75%+14.96%+154.51% 8.19B
Weighted average by Cap. +1.01%+9.86%+29.19%+233.79%

Financials

2026 *2027 *
Net sales 71.57M 62.67M 57.85M 54.02M 102M 6.77B 104M 696M 269M 3.34B 269M 263M 11.59B 79.38M 69.51M 64.17M 59.92M 113M 7.51B 115M 772M 298M 3.7B 298M 292M 12.86B
Net income -16.85M -14.75M -13.62M -12.72M -23.94M -1.59B -24.49M -164M -63.28M -786M -63.28M -61.89M -2.73B -12.67M -11.09M -10.24M -9.56M -18M -1.2B -18.41M -123M -47.56M -591M -47.56M -46.52M -2.05B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26-06-29 US$4.725 +3.17% 79,304
26-06-26 US$4.580 -1.29% 404,582
26-06-25 US$4.640 +2.65% 183,645
26-06-24 US$4.520 +3.79% 122,551
26-06-23 US$4.355 -1.47% 104,156
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.580USD
Average target price
8.571USD
Spread / Average Target
+87.15%

Quarterly revenue - Rate of surprise